Details

Autor(en) / Beteiligte

• Gupta, Shubham
• Khan, Sikandar
• Kawka, Michal
• Gujjuri, Rohan
• Chau, Ian
• Starling, Naureen
• Cunningham, David
• Jiao, Long R
• Gall, Tamara

Titel

Clinical utility of clonal origin determination in managing recurrent hepatocellular carcinoma

Ist Teil von

• Expert review of gastroenterology & hepatology, 2021-10, Vol.15 (10), p.1159-1167

Ort / Verlag

England: Taylor & Francis

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• Recurrence is the driving factor for reduced long-term survival in patients following resected hepatocellular carcinoma (HCC). Extensive research efforts have been conducted to understand the molecular processes precipitating disease recurrence. Modern genomic techniques have identified two distinct mechanisms for recurrent HCC (RHCC): Intrahepatic metastasis (IM-HCC); and multicentric origin (MO-HCC). Medline, EMBASE and Cochrane library were methodically searched for primary research articles in English with the aim of appraising existing literature on the identification of clonal origin of RHCC and its potential clinical utility. Molecular and next-generation sequencing techniques, when applied to clonal origin identification, yield superior accuracy than traditional clinicopathological criteria. Despite various treatment modalities, no optimal therapy has yet been identified for treating clonally differentiated RHCC. Patients with MO-HCC appear to experience improved long-term survival following re-treatment compared to their IM-HCC counterparts (91.7% vs 22.9% 5-year survival, p < 0.001). However, cautious interpretation is advised as heterogeneous classification criteria and small sample sizes restrict the generalizability of such findings. Improved identification of clonal origin in RHCC may facilitate further research on RHCC treatment strategies and enable the development of novel therapeutic targets, potentially leading to individualized treatment approaches in the future.